Answers are grounded in this paper and cite their sources.
Ectomesenchymal chondromyxoid tumor (EMCMT) is a rare mesenchymal indolent neoplasm of the oral cavity, with a marked predilection for the tongue. Extra-glossal tumors are exceedingly rare, and their pathogenesis remains poorly understood. Herein, we retrospectively collected seven extra-glossal and five tongue cases of EMCMT, and examined the molecular features of eleven cases using targeted molecular approaches. EWSR1 , PLAG1 and RREB1::MRTFB rearrangements were evaluated, whereas hotspot mutations in EGFR , BRAF , NRAS , KRAS and PIK3CA were screened by pyrosequencing, and detected mutations were subsequently confirmed by Sanger sequencing. The tumors affected seven male and five female patients with an age range of 12 to 57 years (median, 23.0). The cases occurred in the tongue ( n = 5), palate ( n = 3), alveolar ridge ( n = 2), buccal mucosa ( n = 1) and gingiva ( n = 1). All tumors were treated by local excision; after a median follow-up of 21 months (range, 7–31), three tumors (25.0%) recurred locally and were controlled by re-excision. Morphologically, the tumors were composed of spindle to ovoid-shaped cells arranged in a hyalinized stroma, often demonstrating myxoid and chondroid areas. Cases showed immunoreactivity for podoplanin, S-100 and GFAP and variable (focal or diffuse) reactivity for AE1/AE3 and EMA, and were negative for cytokeratin 7, SMA, calponin and p63. The RREB1 :: MRTFB fusion was detected in all eleven tumors screened (100.0%), and none of the cases investigated showed EWSR1 or PLAG1 rearrangements. Additionally, 7 of 11 tumors screened (63.6%) harbored KRAS mutations, comprising p.G12D alone ( n = 2), KRAS p.G13D ( n = 4), or combined KRAS p.G12D and p.G12V variants ( n = 1). KRAS hotspot mutations, not previously reported in EMCMT, were frequent in this series (mutant allele frequencies, 29.7–54.9%) and invariably co-occurred with RREB1::MRTFB fusion; their clonal allele frequencies indicate an early event, although their biological significance remains to be determined. Local recurrence occurred irrespective of anatomic site or KRAS status. Detection of RREB1::MRTFB fusion remains the most useful ancillary tool to separate EMCMT from its mimics, particularly myoepithelial neoplasms, whereas the diagnostic utility of KRAS testing requires evaluation in larger, controlled cohorts.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: